Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave
Effectiveness of Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave Due to Common Mental Disorders: A Randomized Controlled Trial
The investigators aim to evaluate the effectiveness of Focused Acceptance and Commitment Therapy combined with workplace involvement (FACT-WI) in reducing perceived stress, improving psychological well-being, and supporting return to work among employees on sick leave due to common mental disorders.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
In the present study, participants will be randomly assigned to one of two groups, receiving either Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) or treatment as usual (TAU). FACT-WI will be delivered flexibly according to individual needs over a three-month period, with the possibility of involving the participant's immediate manager to support return to work.
- It is hypothesized that FACT-WI will be more effective than TAU in reducing perceived stress and improving quality of life over time.
- It is hypothesized that participants receiving FACT-WI will return to work more quickly than participants receiving TAU, including both part-time and full-time return to work.
- The feasibility and acceptability of FACT-WI will be evaluated.
- The number and duration of sessions received, as well as the extent and format of workplace involvement, will be explored.
- Managers' experiences of workplace involvement, including its perceived relevance, usefulness, barriers, facilitating factors, and suggestions for improvement, will be explored.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Vita Ligaya Ponce Dalgaard, PhD, MSc
- Phone Number: 004587165805
- Email: ligayadalgaard@psy.au.dk
Study Contact Backup
- Name: Astrid Olesen Liboriussen, MSc
- Phone Number: 004553356030
- Email: astridol@psy.au.dk
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria are (i) age ≥ 18 years, (ii) currently being on part-time or full-time sick leave at the start of the study, (iii) symptoms of anxiety measured with the Generalized Anxiety Disorders (GAD ≥ 9) questionnaire and/or symptoms of depression assessed with the Patient Health Questionnaire (PHQ-9 ≥ 10) and/or symptoms of stress measured with the Perceived Stress Scale (PSS-10 ≥ 17), (iv) Danish language proficiency, (v) ability and willingness to give informed consent, (vi) access to either a smartphone, tablet, or computer with video camera. (vii) Be currently employed and anticipate to continue employment within the organizational setting. (viii)) have been employed in the current organization for a minimum of six months.
Exclusion Criteria:
Exclusion criteria are: (i) currently receiving other psychotherapy for the same problem, (iii) a history of bipolar disorder, (ii) current or past psychotic disorder, (iv) substance abuse or dependence judged to require treatment, (v) suicide risk requiring immediate hospitalization. (vi) being on sick leave for more than 4 months at the time of inclusion. (vii) a somatic or medical condition that is considered to prevent the participant from RTW. (viii) PTSD symptoms that re-quire treatment beyond the scope of the brief intervention. (ix) having an active Section 56 agreement under the Danish Sickness Benefits Act at the time of inclusion. In addition, potential participants must be clinically assessed as suitable for this brief intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: FACT-WI
Brief ACT-based intervention with optional workplace involvement |
Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) is a brief, flexible intervention based on Acceptance and Commitment Therapy (ACT). The intervention aims to increase psychological flexibility, reduce psychological distress, and support return to work. Participants receive up to 300 minutes of online therapist contact over a period of three months. The intervention is tailored to individual needs and focuses on identifying psychological and work-related barriers, promoting values-based action, and developing strategies to support return to work. Workplace involvement is offered when relevant and may include written communication with the participant's immediate manager, verbal contact, or a joint meeting between the participant, manager, and therapist. The purpose is to address work-related barriers and facilitate a sustainable return to work. Workplace involvement is voluntary and requires the participant's consent. |
|
Other: Treatment as Usal (TAU)
Treatment as usual (TAU), including any support or services ordinarily available to employees on sick leave. |
Participants allocated to the control group will receive treatment as usual (TAU). They will have access to the usual healthcare and support services available to employees on sick leave, including relevant services provided by the municipality, workplace, or healthcare system. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived stress
Time Frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
|
Perceived Stress Scale-10 (PSS-10; Cohen & Williamson, 1988). The scale consists of 10 items rated from 0 to 4, resulting in a total score ranging from 0 to 40. Higher scores indicate higher levels of perceived stress (i.e., a negative outcome). |
Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
|
|
Quality of life (well-being)
Time Frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
|
the World Health Organization-5 questionnaire (Bech, 1999; Topp et al., 2015; WHO-5). 5 items are rated on a scale from 0 to 5 with total scores ranging from 0 to 25. Higher scores are indicative of higher levels of life quality (i.e., a positive outcome). |
Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Return to Work (RTW)
Time Frame: From baseline to 3 months (post-treatment) and 6 months (follow-up).
|
Time to return to work, including both part-time and full-time return to work. Using administrative sickness absence records. |
From baseline to 3 months (post-treatment) and 6 months (follow-up).
|
|
Sickness Absence Percentage
Time Frame: At 3 months (post-treatment) and 6 months (follow-up).
|
Percentage of scheduled working time lost due to sickness absence, based on administrative sickness absence records. Higher percentages indicate greater sickness absence (i.e., a negative outcome). |
At 3 months (post-treatment) and 6 months (follow-up).
|
|
Depressive symptoms
Time Frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
|
Patient Health Questionnaire-9 (Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000; PHQ-9). 9 items are rated on a scale from 0 to 3, with a potential total range from 0 to 27. Larger scores mean more depressive symptoms (i.e., a negative outcome). |
Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
|
|
Anxiety symptoms
Time Frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
|
General Anxiety Disorder-7 (Spitzer et al., 2006; GAD-7). 7 items are rated on scale from 0 to 7 with total scores ranging from 0 to 21. Higher scores are indicative of more symptoms of GAD (i.e., a negative outcome). |
Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
|
|
Valued Living
Time Frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
|
Valuing Questionnaire (Smout et al., 2014; VQ). 10 items are rated on a scale from 0 to 6 with total scores ranging from 0 to 60. Higher scores a indicative of actions/life being guided by personally held values (i.e., a positive outcome). |
Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
|
|
Harm/negative effects
Time Frame: Measured once at post-treatment (3 months), in the intervention group only.
|
The Negative Effects Questionnaire (Rozental et al., 2019; NEQ). 32 questions are answered yes/no. If yes, items are rated on a scale from 1 to 5 and participants are asked if the negative effect experience can be attrubuted to the treatment or other crcumstances. Total scores range from 32 to 160 with higher scores indicating more negative effects (i.e., a negative outcome). |
Measured once at post-treatment (3 months), in the intervention group only.
|
|
Experiental Avoidance
Time Frame: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
|
Brief Experiential Avoidance Questionnaire (BEAQ; Gámez et al., 2014). The questionnaire consists of 15 items rated from 1 to 6, resulting in a total score ranging from 15 to 90. Higher scores indicate greater experiential avoidance (i.e., a negative outcome). |
Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
|
|
Client Satisfaction Questionnaire
Time Frame: Measured once at 3 months (follow-up), in the intervention group only.
|
Client Satisfaction Questionnaire-8 (CSQ-8; Larsen et al., 1979). The questionnaire consists of eight items rated from 1 to 4, resulting in a total score ranging from 8 to 32. Higher scores indicate greater satisfaction with the intervention. The questionnaire will be administered to participants in the FACT-WI group only. |
Measured once at 3 months (follow-up), in the intervention group only.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FACT-WI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.